Study | Treatment arms | Design | Study length (weeks) | Enrolled patients (n) | csDMARD-naïve at baseline (yes, no) | Previous biologic therapy (%) | Mean age (years) | Female (%) | Symptom duration (years) | ESR (mm/h) | CRP (mg/l) | DAS28 | HAQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
TCZCOMBI vs. TCZMONO | |||||||||||||
 SURPRISE (2016) | TCZCOMBI | Open label | 52 | 115 | No | 0 | 56 (12) | 87 | 4 (3) | 41 (28) | 12 (15) | 5.1 (1) | 1.0 (0.7) |
 | TCZMONO | 111 | 56 (3) | 87 | 4 (3) | 45 (30) | 18 (26) | 5.3 (1.2) | 1.0 (0.7) | ||||
 FUNCTION (2015) | TCZCOMBI | Double-blind | 52 | 291 | Nof | 0 | 50 (14) | 79 | 6 (6)g | 53 (30) | 26 (30) | 6.7 (1.1) | 1.5 (0.6) |
 | TCZMONO | 292 | 50 (12) | 75 | 6 (6)g | 51 (28) | 25 (32) | 6.7(1.0) | 1.6 (0.7) | ||||
 ACT-RAY (2013) | TCZCOMBI | Open-label, double-blindc | 24 | 277 | No | 0 | 53 (13) | 82 | 8 (8) | NR | NR | 6.3 (1) | 1.5 (0.7) |
 | TCZMONO | 276 | 54 (12) | 79 | 8 (8) | 6.4 (1) | 1.5 (0.6) | ||||||
 ACT-STAR (2013)a | TCZCOMBI | Open-label | 24 | 360 | No | 67 | 54 (12) | 78 | 11 (9) | NR | 14 (21) | 5.5 (1) | NR |
 | TCZMONO | 163 | 87 | 54 (13) | 80 | 14 (10) | 19 (33) | 6.0 (1) | |||||
 CHARISMA (2006)b | TCZCOMBI | Double-blind | 16 | 50 | No | 14 | 50 (NR) | 78 | 11 (NR)c | 39 (NR) | 24 (NR) | 6.5 (NR) | NR |
 | TCZMONO | 52 | 50 (NR) | 73 | 9 (NR)c | 39 (NR) | 22 (NR) | 6.4 (NR) | |||||
TCZCOMBI vs. csDMARD | |||||||||||||
 FUNCTION (2015) | TCZCOMBI | Double-blind | 52 | 291 | No | 0 | 50 (14) | 79 | 6 (6)c | 53 (30) | 26 (30) | 6.7 (1.1) | 1.5 (0.6) |
 | csDMARD | 289 |  | 50 (13) | 80 | 5 (6)c | 50 (27) | 23 (27) | 6.6 (1.0) | 1.5 (0.7) | |||
 ROSE (2012) | TCZCOMBI | Double-blind | 24 | 409 | No | 38 | 55 (12) | 80 | 9 (9) | 46 (24) | 17 (21) | 6.5 (1) | 4.1 (1.7)h |
 | csDMARD | 205 | 38 | 56 (12) | 84 | 9 (9) | 47 (22) | 17 (22) | 6.6 (1) | 4.0 (2.1)h | |||
 LITHE (2011)a | TCZCOMBI | Double-blindd | 52 | 398 | No | 11 | 53 (12) | 82 | 9 (NR) | 46 (25) | 23 (26) | 6.6 (1) | 1.5 (0.6) |
 | csDMARD | 393 | 12 | 51 (12) | 83 | 9 (NR) | 47 (25) | 22 (25) | 6.5 (1) | 1.5 (0.6) | |||
 TOWARD (2008) | TCZCOMBI | Double-blind | 24 | 803 | No | NS | 53 (13) | 81 | 10 (9) | 48 (28) | 26 (32) | 6.7 (1) | 1.5 (0.6) |
 | csDMARD | 413 | 54 (13) | 84 | 10 (9) | 49 (28) | 26 (47) | 6.6 (1) | 1.5 (0.6) | ||||
 OPTION (2008)a | TCZCOMBI | Double-blind | 24 | 205 | No | 5 | 51 (12) | 85 | 8 (7) | 51 (27) | 26 (26) | 6.8 (1) | 1.6 (0.6) |
 | csDMARD | 204 | 9 | 51 (12) | 78 | 8 (7) | 50 (26) | 24 (28) | 6.8 (1) | 1.5 (0.6) | |||
 RADIATE (2008)a | TCZCOMBI | Double-blind | 24 | 170 | No | 100 | 54 (13) | 84 | 13 (9) | 49 (28) | 28 (33) | 6.8 (1) | 1.7 (0.6) |
 | csDMARD | 158 | 53 (13) | 79 | 11 (9) | 55 (33) | 37 (41) | 6.8 (1) | 1.7 (0.6) | ||||
 CHARISMA (2006)b | TCZCOMBI | Double-blind | 16 | 50 | No | 14 | 50 (NR) | 78 | 11 (NR)c | 39 (NR) | 24 (NR) | 6.5 (NR) | NR |
 | csDMARD | 49 | 51 (NR) | 78 | 11 (NR)c | 43 (NR) | 32 (NR) | 6.8 (NR) | |||||
TCZMONO vs. csDMARD | |||||||||||||
 FUNCTION (2015) | TCZMONO | Double-blind | 52 | 292 | No | 0 | 50 (12) | 75 | 6 (6)c | 51 (28) | 25 (32) | 6.7(1.0) | 1.6 (0.7) |
 | csDMARD | 289 | 50 (13) | 80 | 5 (6)c | 50 (27) | 23 (27) | 6.6 (1.0) | 1.5 (0.7) | ||||
 AMBITION (2010) | TCZMONO | Double-blind | 24 | 286 | No | 8 | 51 (13) | 83 | 6 (8) | 50 (28) | 30 (33) | 6.8 (1) | 1.6 (0.7) |
 | csDMARD | 284 | 7 | 50 (13) | 79 | 6 (8) | 49 (26) | 31 (34) | 6.8 (1) | 1.5 (0.6) | |||
 SATORI (2009) | TCZMONO | Double-blind | 24 | 61 | No | NS | 53 (11) | 90 | 9 (8) | 52 (28) | 30 (20) | 6.1 (1) | NR |
 | csDMARD | 64 | 51 (12) | 75 | 9 (7) | 52 (24) | 32 (26) | 6.2 (1) | |||||
 SAMURAI (2007) | TCZMONO | Open-labele | 52 | 157 | No | NS | 53 (12) | 80 | 2 (1) | 71 (28) | 47 (29) | 6.5 (1) | NR |
 | csDMARD | 145 | 53 (13) | 82 | 2 (1) | 71 (25) | 49 (29) | 6.4 (1) | |||||
 CHARISMA (2006)b | TCZMONO | Double-blind | 16 | 52 | No | 14 | 50 (NR) | 73 | 9 (NR)c | 39 (NR) | 22 (NR) | 6.4 (NR) | NR |
 | csDMARD | 49 | 51 (NR) | 78 | 11 (NR)c | 43 (NR) | 32 (NR) | 6.8 (NR) |